# US 2015/0147330 A1 · High-affinity monoclonal antibodies to glypican-3 and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147330 A1
- Document ID: US20150147330A1
- Status: Published application
- Kind: A1
- Application number: 14/403,896
- Filed: 2013-05-31
- Published: 2015-05-28
- Earliest claimed: 2012-06-01
- Assignees: The United States of America as represented by the Secretary, Department of Health and Human Service
- Applicants: The United States of America,as represented by the Secretary, Department of Health and Human Service
- Inventors: Mitchell Ho; Yen T. Phung; Wei Gao; Yifan Zhang
- Web page: https://patentgrep.com/patent/US20150147330A1

## CPC

- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A61K 38/45: Transferases (2)
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/30: from tumour cells
- C07K 16/303: {Liver or Pancreas}
- G01N 33/5752: of the lungs
- G01N 33/57525: of the liver or pancreas
- G01N 33/57545: of the ovaries
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12Y 204/02036: NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2458/00: Labels used in chemical analysis of biological material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

Described herein is the identification of a panel of high affinity monoclonal antibodies that bind GPC3. The disclosed antibodies recognize native GPC3 on the surface of cancer cells, as well as soluble GPC3. The highest affinity antibody (YP7) was further characterized and shown to be highly sensitive in that it was capable of detecting cancer cells with low expression of GPC3. YP7 also exhibited significant HCC tumor growth inhibition in vivo. Immunotoxins comprising the antibodies disclosed herein fused to PE38 exhibited very high binding affinity for GPC3-expressing cells and significantly inhibited GPC3-expressing cancer cell growth. Thus, the high-affinity monoclonal antibodies disclosed herein can be used for the diagnosis and treatment of GPC3-expressing cancers.

## Claims

### Claim 1

An isolated monoclonal antibody that binds glypican-3 (GPC3), wherein:
(i) the heavy chain of the antibody comprises SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40, and the light chain of the antibody comprises SEQ ID NO: 44, amino acid residues 56-58 of SEQ ID NO: 14, and SEQ ID NO: 45; or
(ii) the heavy chain of the antibody comprises SEQ ID NO: 41, SEQ ID NO: 42 and SEQ ID NO: 43, and the light chain of the antibody comprises SEQ ID NO: 46, SEQ ID NO: 47 and SEQ ID NO: 45.

### Claim 2 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein:
(i) the heavy chain of the antibody comprises amino acid residues 26-33, 51-60 and 99-106 of SEQ ID NO: 12, and the light chain of the antibody comprises amino acid residues 27-38, 56-58 and 95-103 of SEQ ID NO: 14;
(ii) the heavy chain of the antibody comprises amino acid residues 26-33, 51-60 and 99-106 of SEQ ID NO: 8, and the light chain of the antibody comprises amino acid residues 27-38, 56-58 and 95-103 of SEQ ID NO: 10;
(iii) the heavy chain of the antibody comprises amino acid residues 26-33, 51-60 and 99-106 of SEQ ID NO: 16, and the light chain of the antibody comprises amino acid residues 27-38, 56-58 and 95-103 of SEQ ID NO: 18; or
(iv) the heavy chain of the antibody comprises amino acid residues 26-33, 51-60 and 99-106 of SEQ ID NO: 20, and the light chain of the antibody comprises amino acid residues 27-38, 56-58 and 95-103 of SEQ ID NO: 22, amino acid residues 27-38, 56-58 and 95-103 of SEQ ID NO: 24 or amino acid residues 27-38, 56-58 and 95-103 of SEQ ID NO: 26.

### Claim 3 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein:
(i) the heavy chain of the antibody comprises amino acid residues 31-35, 50-68 and 101-106 of SEQ ID NO: 12 and the light chain of the antibody comprises amino acid residues 24-40, 56-62 and 95-103 of SEQ ID NO: 14;
(ii) the heavy chain of the antibody comprises amino acid residues 31-35, 50-68 and 101-106 of SEQ ID NO: 8 and the light chain of the antibody comprises amino acid residues 24-40, 56-62 and 95-103 of SEQ ID NO: 10;
(iii) the heavy chain of the antibody comprises amino acid residues 31-35, 50-68 and 101-106 of SEQ ID NO: 16 and the light chain of the antibody comprises amino acid residues 24-40, 56-62 and 95-103 of SEQ ID NO: 18; or
(iv) the heavy chain of the antibody comprises amino acid residues 31-35, 50-68 and 101-106 of SEQ ID NO: 20 and the light chain of the antibody comprises amino acid residues 24-40, 56-62 and 95-103 of SEQ ID NO: 22, amino acid residues 24-40, 56-62 and 95-103 of SEQ ID NO: 24 or amino acid residues 24-40, 56-62 and 95-103 of SEQ ID NO: 26.

### Claim 4 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein:
(i) the amino acid sequence of the heavy chain is at least 90% or at least 95% identical to SEQ ID NO: 12; and the amino acid sequence of the light chain is at least 90% or at least 95% identical to SEQ ID NO: 14;
(ii) the amino acid sequence of the heavy chain is at least 90% or at least 95% identical to SEQ ID NO: 8; and the amino acid sequence of the light chain is at least 90% or at least 95% identical to SEQ ID NO: 10;
(iii) the amino acid sequence of the heavy chain is at least 90% or at least 95% identical to SEQ ID NO: 16; and the amino acid sequence of the light chain is at least 90% or at least 95% identical to SEQ ID NO: 18; or
(iv) the amino acid sequence of the heavy chain is at least 90% or at least 95% identical to SEQ ID NO: 20; and the amino acid sequence of the light chain is at least 90% or at least 95% identical to SEQ ID NO: 22, 24 or 26.

### Claim 5 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein:
(i) the heavy chain of the antibody comprises SEQ ID NO: 12 and the light chain of the antibody comprises SEQ ID NO: 14;
(ii) the heavy chain of the antibody comprises SEQ ID NO: 8 and the light chain of the antibody comprises SEQ ID NO: 10;
(iii) the heavy chain of the antibody comprises SEQ ID NO: 16 or SEQ ID NO: 37 and the light chain of the antibody comprises SEQ ID NO: 18; or
(iv) the heavy chain of the antibody comprises SEQ ID NO: 20 and the light chain of the antibody comprises SEQ ID NO: 22, 24 or 26.

### Claim 6

An isolated monoclonal antibody that binds GPC3, wherein the antibody comprises:
(i) a variable heavy (VH) domain comprising the amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 37 or SEQ ID NO: 20; or
(ii) a variable light (VL) domain comprising the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 10, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24 or SEQ ID NO: 26; or
(iii) both (i) and (ii).

### Claim 7 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein the antibody is a VH single-domain antibody, a Fab fragment, a Fab′ fragment, a F(ab)′2 fragment, a single chain variable fragment (scFv), or a disulfide stabilized variable fragment (dsFv).

### Claim 8 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein the antibody is an IgG.

### Claim 9 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein the antibody is labeled.

### Claim 10 (depends on 9)

The isolated monoclonal antibody of claim 9, wherein the label is a fluorescence, enzymatic, or radioactive label.

### Claim 11 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody is a humanized monoclonal antibody.

### Claim 12 (depends on 1)

A composition comprising a therapeutically effective amount of the antibody of claim 1 in a pharmaceutically acceptable carrier.

### Claim 13 (depends on 1)

An isolated immunoconjugate comprising the monoclonal antibody of claim 1 and an effector molecule.

### Claim 14 (depends on 13)

The isolated immunoconjugate of claim 13, wherein the effector molecule is a toxin.

### Claim 15 (depends on 14)

The isolated immunoconjugate of claim 14, wherein the toxin is Pseudomonas exotoxin or a variant thereof.

### Claim 16 (depends on 15)

The isolated immunoconjugate of claim 15, wherein the toxin is PE38 comprising the amino acid sequence of SEQ ID NO: 1.

### Claim 17 (depends on 13)

The isolated immunoconjugate of claim 13, comprising the amino acid sequence of residues 2-597 of SEQ ID NO: 35, residues 2-597 of SEQ ID NO: 28, residues 2-597 of SEQ ID NO: 31, or residues 2-597 of SEQ ID NO: 33.

### Claim 18 (depends on 13)

The isolated immunoconjugate of claim 13, wherein the effector molecule is a detectable label.

### Claim 19 (depends on 13)

A composition comprising a therapeutically effective amount of the isolated immunoconjugate of claim 13 in a pharmaceutically acceptable carrier.

### Claim 20 (depends on 12)

A method of treating a subject with cancer, comprising selecting a subject with a cancer that expresses GPC3 and administering to the subject a therapeutically effective amount of the composition of claim 12, thereby treating the cancer in the subject.

### Claim 21 (depends on 12)

A method of inhibiting tumor growth or metastasis, comprising selecting a subject with a cancer that expresses GPC3 and administering to the subject a therapeutically effective amount of the composition of claim 12, thereby inhibiting tumor growth or metastasis.

### Claim 22 (depends on 1)

A method of determining if a subject has cancer, or a method of confirming the diagnosis of cancer in a subject, comprising:
contacting a sample from the subject with the monoclonal antibody of claim 1; and
detecting binding of the antibody to the sample,
wherein an increase in binding of the antibody to the sample as compared to binding of the antibody to a control sample identifies the subject as having cancer, or confirms the diagnosis of cancer in the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the monoclonal antibody is directly labeled.

### Claim 24 (depends on 22)

The method of claim 22, further comprising:
contacting a second antibody that specifically binds the monoclonal antibody with the sample, and
detecting the binding of the second antibody,
wherein an increase in binding of the second antibody to the sample as compared to binding of the second antibody to a control sample detects cancer in the subject or confirms the diagnosis of cancer in the subject.

### Claim 25 (depends on 22)

The method of claim 22, wherein the cancer is hepatocellular carcinoma (HCC), melanoma, squamous cell carcinoma of the lung or ovarian clear cell carcinoma.

### Claim 26 (depends on 1)

An isolated nucleic acid molecule encoding the monoclonal antibody of claim 1.

### Claim 27 (depends on 26)

The isolated nucleic acid molecule of claim 26, wherein:
(i) the nucleotide sequence encoding the heavy chain of the monoclonal antibody comprises SEQ ID NO: 11 and the nucleotide sequence encoding the light chain of the monoclonal antibody comprises SEQ ID NO: 13;
(ii) the nucleotide sequence encoding the heavy chain of the monoclonal antibody comprises SEQ ID NO: 7 and the nucleotide sequence encoding the light chain of the monoclonal antibody comprises SEQ ID NO: 9;
(iii) the nucleotide sequence encoding the heavy chain of the monoclonal antibody comprises SEQ ID NO: 15 or SEQ ID NO: 36 and the nucleotide sequence encoding the light chain of the monoclonal antibody comprises SEQ ID NO: 17; or
(iv) the nucleotide sequence encoding the heavy chain of the monoclonal antibody comprises SEQ ID NO: 19 and the nucleotide sequence encoding the light chain of the monoclonal antibody comprises SEQ ID NO: 21, SEQ ID NO: 23 or SEQ ID NO: 25.

### Claim 28 (depends on 26)

An expression vector comprising the isolated nucleic acid molecule of claim 26.

### Claim 29 (depends on 28)

An isolated host cell transformed with the expression vector of claim 28.

### Claim 30 (depends on 19)

A method of treating a subject with cancer, comprising selecting a subject with a cancer that expresses GPC3 and administering to the subject a therapeutically effective amount of the composition of claim 19, thereby treating the cancer in the subject.

### Claim 31 (depends on 19)

A method of inhibiting tumor growth or metastasis, comprising selecting a subject with a cancer that expresses GPC3 and administering to the subject a therapeutically effective amount of the composition of claim 19, thereby inhibiting tumor growth or metastasis.
